They are often used to manage conditions such as hand dermatitis, diaper rash, and very dry skin. Hands are exposed to the ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...

Basically, this means that the petrolatum in both products will prevent water loss (and your skin and lips from drying out), ...

Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Good day, and welcome to the Arcutis Biotherapeutics 2024 Third ...

Retinal, a derivative of vitamin A, works in various ways to improve the appearance of your skin. Here’s how to determine how ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.

Eczema affects millions of Americans, and any number of environmental and health factors can trigger flare-ups. What should ...

Incyte (Nasdaq:INCY) today reports 2024 third quarter financial results, and provides a status update on the Company’s clinical development portfolio. "In the third quarter of 2024, we delivered ...